(Q34480473)
Statements
Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy (English)
Mariana Serpa
Flávia Xavier
Cláudia Bitti Barroso
Monika Conchon
Pedro Enrique Dorlhiac-Llacer
19 December 2010
1 reference